Affymax, Inc. Completes Enrollment in Phase 3 Program for Hematide in Chronic Renal Failure with Completion of Enrollment in EMERALD 2, the Final of Four Phase 3 Clinical Trials of Hematide(TM)

PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in the remaining Phase 3 clinical trial of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. EMERALD 2 is fully enrolled with over 800 dialysis patients, collectively, from over 90 sites in the United States and Europe.